MRC Technology Collaborates with RDL on Infectious Disease Diagnostics

MRC Technology's expertise and experience will allow us to accelerate development of our assay portfolio, enhancing the capabilities of the RenDx platform and providing end users with additional value and flexibility.”

Mike Dalrymple, MRC Technology added, “MRC Technology will build a capability in early stage translation of diagnostic opportunities from academia at our laboratory facilities in Edinburgh.”

The RenDx Multiplex Assay System provides a new approach to multiplex DNA detection. Starting from the user's existing extraction and amplification methods, the assay utilizes purpose-designed instrumentation to automate the processing and detection of up to nine targets in a single sample. The RenDx multiplex assay system is based on surface enhanced resonance Raman scattering, providing automated, multiplex, high sensitivity, in vitro screening for clinical research.

MRC Technology is an independent life science technology transfer charity, offering professional services to organizations within the academic, charity, biotechnology, and pharmaceutical sectors globally. Its goal is to ensure that innovative life science research reaches its full potential. The company provides technology transfer services, identifying and protecting research, and partnering it with industry to continue development to market. Services include IP management, research, and development for diagnostics, small molecules, and therapeutic antibodies.

Renishaw Diagnostics Ltd is a subsidiary of the Renishaw Group, a global supplier of engineering technologies, medical devices, and Raman spectroscopy systems. Renishaw's products are used in diverse applications such as machine tool automation, additive manufacturing, and medical technologies.

Related Links:
MRC Technology Ltd
RDL